V Fonseca
Overview
Explore the profile of V Fonseca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davidson J, Desouza C, Fonseca V, Frias J, Van Gaal L, Giorgino F, et al.
Diabet Med
. 2019 Aug;
37(2):256-266.
PMID: 31365765
Aims: Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA levels. We investigated the relationship between achievement of American Diabetes Association (ADA) and American Association of Clinical Endocrinologists...
2.
Faria N, Kraemer M, Hill S, Goes de Jesus J, Aguiar R, Iani F, et al.
Science
. 2018 Aug;
361(6405):894-899.
PMID: 30139911
The yellow fever virus (YFV) epidemic in Brazil is the largest in decades. The recent discovery of YFV in Brazilian species mosquitos highlights a need to monitor the risk of...
3.
Sun D, Wang T, Heianza Y, Huang T, Shang X, Lv J, et al.
Int J Obes (Lond)
. 2017 Sep;
42(1):20-27.
PMID: 28925411
Background/objectives: Prenatal growth, which is widely marked by birthweight, may have a pivotal role in affecting the lifelong risk of cardiometabolic disorders; however, comprehensive evaluation of its relations with childhood...
4.
Lopes P, Mendes L, Fonseca V, Villasante S
J Environ Manage
. 2017 Jun;
200:123-134.
PMID: 28575780
Although critical tools for protecting ocean habitats, Marine Protected Areas (MPAs) are sometimes challenged for social impacts and conflicts they may generate. Some conflicts have an economic base, which, once...
5.
Montanya E, Fonseca V, Colagiuri S, Blonde L, Donsmark M, Nauck M
Diabetes Obes Metab
. 2015 Dec;
18(7):707-10.
PMID: 26662611
In the liraglutide clinical trial programme, liraglutide 1.2 and 1.8 mg were found to effectively lower glycated haemoglobin (HbA1c) in patients with type 2 diabetes (T2D). It is unknown whether...
6.
Fonseca V, Zhu T, Karyekar C, Hirshberg B
Diabetes Obes Metab
. 2011 Dec;
14(4):365-71.
PMID: 22192246
Aim: To investigate whether patients taking metformin for type 2 diabetes mellitus (T2DM) have improved glycaemic control without compromising tolerability by adding an agent with a complementary mechanism of action...
7.
Fonseca V, Gill J, Zhou R, Leahy J
Diabetes Obes Metab
. 2011 Apr;
13(9):814-22.
PMID: 21481127
Aim: To evaluate the benefits of initiating insulin at an earlier versus later treatment stage, and regimens with/without sulfonylurea (SU). Methods: Pooled analysis of 11 prospective randomized clinical trials, including...
8.
Toprani A, Fonseca V
Diabetes Obes Metab
. 2011 Jan;
13(3):276-80.
PMID: 21205120
Aim: The thiazolidinedione (TZD) class of antihyperglycaemic agents has been shown to improve glycaemic control by improving peripheral insulin sensitivity but may worsen or precipitate congestive heart failure (CHF). Randomized...
9.
Matthews D, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, et al.
Diabetes Obes Metab
. 2010 Jul;
12(9):780-9.
PMID: 20649630
Aim: To show that vildagliptin added to metformin is non-inferior to glimepiride in reducing HbA1c levels from baseline over 2 years. Methods: A randomized, double-blind, active-comparator study of patients with...
10.
Rosenstock J, Fonseca V, McGill J, Riddle M, Halle J, Hramiak I, et al.
Diabetologia
. 2009 Jul;
52(9):1971-3.
PMID: 19609501
No abstract available.